###### Key Messages

-   At baseline, the prevalence of seven symptoms differed between organisms groups

-   Those with a virus detected had higher severity of symptoms during follow-up

-   Most patients had mild symptoms after 1 week regardless of aetiology

Introduction {#s1}
============

Acute respiratory tract infections are the most common infection presenting to primary care ([@CIT0001]) with between 40% and 70% of adults suffering at least one episode annually ([@CIT0002]). They are the most common reason for antibiotic prescriptions in primary care ([@CIT0003]) despite the majority having a viral aetiology ([@CIT0004]). Up to 70% presenting with cough and bronchitis, will receive an antibiotic prescription ([@CIT0005], [@CIT0006]). Yet, the Cochrane meta-analysis of 17 randomized controlled trials, suggest little benefit from antibiotics in these conditions ([@CIT0007]).

The factors influencing the prescription of an antibiotic are complex ([@CIT0008], [@CIT0009]). Among the factors clinicians cite is the uncertainty in distinguishing bacterial from viral infections ([@CIT0010], [@CIT0011]), particularly in 'middle cases' ([@CIT0012]), while the perceived severity of illness and the impact on social roles, influence patients' decisions to consult ([@CIT0013], [@CIT0014]).

Clinical findings traditionally used to guide antibiotic prescribing in primary care correlate poorly with outcome ([@CIT0015]), although more complex clinical scores can identify those at risk of adverse outcome ([@CIT0018]). The use of point of care tests (POCTs), such as C-Reactive Protein, can distinguish more patients as low risk and reduces antibiotic prescriptions ([@CIT0019]). Nucleic acid amplification tests (NAATs) that identify infecting organisms have the potential to increase the diagnostic accuracy, inform prognosis and guide antimicrobial therapy. Therefore, the development of NAATs as POCTs could influence management decisions ([@CIT0020]).

Our aims were to describe differences in clinical presentation and clinical course between patients with viruses or bacteria detected using real-time polymerase chain reaction (PCR) on throat swabs. Identifying features that make viral infections more likely could help support GPs to avoid antibiotic prescriptions and provide an evidence base for the use of POCTs to improve therapeutic decision making and provide prognostic information to inform patients of the likely duration of their symptoms.

Methods {#s2}
=======

Study population {#s3}
----------------

The participants included in this investigation are a subcohort (3C Plus) of the prospective Cough Complication Cohort (3C) study. Thirteen practices in the south of England, which were already participating in the 3C study, agreed to take part in 3C Plus. The methods for recruitment and data collection are similar to those in the parent cohort ([@CIT0021], [@CIT0022]). Briefly, the participants were patients aged 16 years and older who presented to UK general practices with a first episode of acute cough of less than 28 days duration between April and December 2013.

At baseline, participants answered questionnaires and provided data on their sociodemographic and medical history. Participants underwent a clinical assessment including severity (mild, moderate, or severe) of their symptoms and had vital signs measured.

Outcomes {#s4}
--------

At baseline, the participants were provided with a symptom diary in which they were asked to record the severity of their symptoms from Day 0 (baseline) until Day 7. Symptom severity was rated as 0 (not present), 1 (present, no problem), 2 (present, mild problem), 3 (present, moderate problem), and 4 (present, severe problem). The participants also recorded their temperature at the same time each day, but at least 2 hours after taking any antipyretic for the 7 days after clinical examination using disposable thermometers (TempaDot^TM^) provided to them.

Using the participants' reported symptom severity, we created two outcomes as defined elsewhere ([@CIT0023]) to allow comparability with previous studies: (i) average symptom score severity between Days 2 to 4 inclusive, and (ii) longest duration of any symptom rated by the participants as moderate or severe during the 7 days after consultation. For (i), we took the average severity for each symptom in Days 2 to 4, and then took the average of these scores across all symptoms. Severity scores that were missing on a particular day were ignored in the calculations. For (ii), we censored participants who reported moderate or severe symptoms on their last day of follow-up. The number of patients with missing outcome data was greater for outcome 1 than for outcome 2, due to some patients having reported their symptoms only on Day 1.

Microbiological sampling {#s5}
------------------------

Clinicians were instructed on taking oropharyngeal swabs using a nylon-flocked swab by gently swabbing between the tonsullar pillars and the tonsules on both sides of the throat. Swabs were transported to the Nuffield Department of Medicine Laboratory at the Oxford University Hospitals NHS Foundation Trust Hospital in 2 ml eNAT Transport and Preservation medium (COPAN Italia), where they were stored at −80°C until transport to the South West Regional Laboratory, PHE, Bristol. The study was approved by Oxford Research Ethics Committee A (09/H0604/67).

Microbe identification and grouping {#s6}
-----------------------------------

Identification of 10 viruses and 11 bacteria ([Supplementary Material 1](#sup1){ref-type="supplementary-material"}) from throat swabs was done by real-time PCR using Taqman Low Density Array cards as described elsewhere ([@CIT0024]). We divided the participants into 4 groups depending on the detection of organisms: (i) no organisms detected, (ii) ≥1 virus, but no bacteria (iii) ≥1 bacteria, but no viruses, or (iv) ≥1 virus and ≥1 bacteria. In the primary analysis, we used the same classification for bacterial pathogens as the GRACE study ([@CIT0004]). In brief, this means six of the bacteria detected were not considered as pathogenic, and therefore not used to guide categorization of patients into groups (iii and iv). In a sensitivity analysis, we made no assumptions on whether bacteria were likely to have a role in pathogenicity or asymptomatic carriage and included all bacteria identified.

Statistical analyses {#s7}
--------------------

Details on sample size calculation are provided in [Supplementary Material 2](#sup2){ref-type="supplementary-material"}.

We described the baseline characteristics across the four groups using means and SDs for continuous variables, and number and percentages for categorical variables. We used analysis of variance and chi-squared tests to assess dependence between the groups and continuous and categorical baseline variables, respectively.

We used linear regression models to estimate mean differences (MD) and 95% confidence intervals (CI) in outcomes 1 and 2 among the four groups, with the group with no organisms as reference. We used both unadjusted models and models adjusting for age, reported duration of illness before presentation, and antibiotic prescription.

We also analysed differences in the medians for outcome 2 between groups with Kaplan-Meier curves and the log-rank test using the R packages 'survival' and 'survminer' ([@CIT0025], [@CIT0026]). Cox proportional hazards regression was used to adjust for the same covariates as above. The proportional hazards assumption was tested and there was no evidence this assumption was violated.

We performed similar analyses to compare those with and without the most common organisms, that is, those present in more than 10% of the sample, adjusting additionally for co-infection with other viruses and/or bacteria.

We plotted means and 95% CIs of symptom severity score from Day 1 to Day 7 by group, for all symptoms combined. Although the outcome measure averaged across all symptoms, to show the possible effect on specific symptoms we also showed these graphically without performing additional hypothesis tests.

All statistical tests were two-sided using a significance level of 5% and we reported all outcome results with 95% CIs. Analyses were carried out using R (version 3.6.0) ([@CIT0027]).

Results {#s8}
=======

Overall, 645 participants completed the baseline assessment and provided throat swab samples. Of these, 354 filled in the symptom diary over the 7 days after baseline inclusion ([Supplementary Material 3](#sup3){ref-type="supplementary-material"}). Those who completed the symptom diary were older and more likely to have received antibiotics, to have higher systolic blood pressure at presentation, lower pulse rate, lower oxygen saturation, less likely to smoke, and to report muscle aches. There were no differences in the distribution of completers and no completers across organism groups ([Supplementary Material 4](#sup4){ref-type="supplementary-material"}).

[Table 1](#T1){ref-type="table"} shows the number of study participants in each of the four groups and the organisms identified in the throat swab. The largest group comprised those with no organisms detected (*n* = 299, 46.4%), followed by those with viruses detected but no bacteria (*n* = 151, 23.4%), those with bacteria detected but no virus (*n* = 120, 18.6%), and those with both viruses and bacteria (*n* = 75, 11.6%). *Haemophilus influenzae* was the commonest organism (*n* = 166, 25.7%), followed by Picornavirus group (*n* = 165, 25.6%). The frequencies for the bacteria included in the sensitivity analyses across groups are shown in [Supplementary Material 5](#sup5){ref-type="supplementary-material"}.

###### 

Frequencies of organisms identified by PCR in the prospective Cough Complication Cohort (3C) Plus study 2013

                                   Overall (*n* = 645)   Organism group                                          
  -------------------------------- --------------------- ---------------- ---- ----- -------- ---- -------- ---- --------
  **Virus, *n* (%)**                                                                                             
  * Picornavirus* ^a^              165                   (25.6)           \-   105   (16.3)   \-            60   (9.3)
  * Human parainfluenza virus*     21                    (3.3)            \-   19    (2.9)    \-            2    (0.3)
  * Respiratory syncytial virus*   20                    (3.1)            \-   16    (2.5)    \-            4    (0.6)
  * Influenza A*                   10                    (1.5)            \-   6     (0.9)    \-            4    (0.6)
  * Human coronavirus*             9                     (1.4)            \-   5     (0.8)    \-            4    (0.6)
  * Human metapneumovirus*         2                     (0.3)            \-   1     (0.2)    \-            1    (0.2)
  * Influenza B*                   1                     (0.2)            \-   1     (0.2)    \-            0    (0.0)
  * Adenovirus*                    1                     (0.2)            \-   1     (0.2)    \-            0    (0.0)
  * Bocavirus*                     0                     (0.0)            \-   0     (0.0)    \-            0    (0.0)
  * Parechovirus*                  0                     (0.0)            \-   0     (0.0)    \-            0    (0.0)
  **Bacteria, *n* (%)**                                                                                          
  * Haemophilus influenzae*        166                   (25.7)           \-   \-             98   (15.2)   68   (10.5)
  * Streptococcus pneumoniae*      24                    (3.7)            \-   \-             11   (1.7)    13   (2.0)
  * Bordetella pertussis*          3                     (0.5)            \-   \-             2    (0.3)    1    (0.2)
  * Chlamydia pneumoniae*          3                     (0.5)            \-   \-             3    (0.5)    0    (0.0)
  * Mycoplasma pneumoniae*         2                     (0.3)            \-   \-             2    (0.3)    0    (0.0)

^a^Picornavirus group combines organisms identified as either in Enterovirus genus or *Rhinovirus* species.

The baseline characteristics of participants in the four groups are summarized in [Table 2](#T2){ref-type="table"}. Patients with no organisms detected were older and patients with both bacteria and viruses detected were younger. The reported duration of illness before clinical presentation was shorter for those with a viral infection alone, although the illness was not perceived as having worsened differently between groups. Antibiotics were prescribed to 232 patients with no organism detected (77.6%), and to 117 patients with virus alone (77.5%), and to 83 patients with bacteria alone (69.2%). Smoking status did not vary across groups, but among past smokers, there were significant differences in years since cessation between organism groups. Seven symptoms were reported more commonly in those with virus alone, than among those with bacteria alone or no infection. The same symptoms, except muscle aches, were also reported more commonly in those with both virus and bacteria combined, than among those with a bacteria or virus alone. There were no significant differences in vital signs across the four groups.

###### 

Baseline characteristics by pathogenic group in the prospective Cough Complication Cohort (3C) Plus study 2013

  Baseline characteristic                     Organism group   *P*-value                                                   
  ------------------------------------------- ---------------- ----------- ------ -------- ------ -------- ------ -------- -------------
  **Age (years), Mean (SD)**                  51.4             (17.8)      50.4   (17.8)   49.5   (18.5)   45.0   (19.2)   **0.049**
  **Sex, *N* (%)**                                                                                                         **0.151**
   Male                                       94               (31.4)      55     (36.4)   50     (41.7)   31     (41.3)   
   Female                                     205              (68.6)      96     (63.6)   70     (58.3)   44     (58.7)   
  **Duration of illness (days), Mean (SD)**   9.9              (6.51)      8.1    (5.53)   11.5   (7.12)   8.9    (5.79)   **\<0.001**
  **Illness worsening, *N* (%)**              215              (71.9)      118    (78.1)   90     (75.0)   64     (85.3)   0.086
  **Antibiotics prescribed, *N* (%)**                                                                                      **0.009**
   No                                         67               (22.4)      34     (22.5)   37     (30.8)   10     (13.3)   
   Delayed                                    29               (9.70)      15     (9.93)   12     (10.0)   17     (22.7)   
   Immediate                                  203              (67.5)      102    (67.5)   71     (59.2)   48     (64.0)   
  **Smoking status, *N* (%)**                                                                                              0.211
   Never                                      124              (41.5)      55     (36.4)   46     (38.3)   30     (40.0)   
   Past                                       90               (30.1)      40     (26.5)   37     (30.8)   14     (18.7)   
    Years since cessation, Mean (SD)          15.6             (14.3)      24.8   (17.6)   13.2   (12.9)   16.8   (15.6)   **0.003**
   Current                                    85               (28.4)      56     (37.1)   37     (30.8)   31     (41.3)   
    Pack-years, Mean (SD)                     19.8             (17.1)      17.4   (15.6)   20.9   (28.7)   18.3   (19.0)   0.824
  **Symptoms, *N* (%)**                                                                                                    
   Blocked or runny nose                      202              (67.6)      123    (81.5)   79     (65.8)   63     (84.0)   **\<0.001**
   Fever                                      129              (43.1)      86     (57.0)   67     (55.8)   50     (66.7)   **\<0.001**
   Muscle aches all over                      168              (56.2)      102    (67.5)   47     (39.2)   39     (52.0)   **\<0.001**
   Sputum                                     203              (67.9)      117    (77.5)   86     (71.7)   67     (89.3)   **0.001**
   Crackles                                   169              (56.5)      93     (61.3)   55     (45.8)   53     (70.7)   **0.004**
   Wheeze                                     71               (23.7)      45     (29.8)   24     (20.0)   29     (38.7)   **0.016**
   Chills/shivering                           122              (40.8)      68     (45.0)   51     (42.5)   44     (58.7)   **0.047**
   Disturbed sleep                            244              (81.6)      134    (88.7)   108    (90.0)   67     (89.3)   0.049
   Wet or productive cough                    229              (76.6)      115    (76.2)   99     (82.5)   67     (89.3)   0.057
   Chest pain                                 112              (37.5)      62     (41.1)   53     (44.2)   38     (50.7)   0.176
   Bronchial breathing                        13               (4.3)       10     (6.6)    7      (5.8)    8      (10.7)   0.211
   Shortness of breath                        238              (79.6)      118    (78.1)   85     (70.8)   61     (81.3)   0.213
   Diarrhoea                                  33               (11.0)      19     (12.6)   20     (16.7)   7      (9.33)   0.362
   Confusion/disorientation                   19               (6.35)      12     (7.95)   8      (6.67)   9      (12.0)   0.401
   Dry cough                                  188              (62.9)      96     (63.6)   85     (70.8)   51     (68.0)   0.420
   Headache                                   165              (55.2)      88     (58.3)   71     (59.2)   46     (61.3)   0.735
  **Vital Signs, Mean (SD)**                                                                                               
   Respiratory rate (breaths/min)             17.1             (3.96)      16.7   (3.57)   16.2   (4.28)   16.5   (3.84)   0.154
   Pulse (beats/min)                          80.3             (12.9)      81.2   (13.1)   81.6   (14.1)   83.6   (12.5)   0.245
   SBP (mmHg)                                 126              (17.6)      127    (16.5)   127    (15.7)   124    (16.3)   0.425
   DBP (mmHg)                                 76.0             (10.5)      76.0   (10.5)   76.0   (10.2)   75.1   (9.31)   0.922
   Oxygen Saturation (%)                      97.3             (1.67)      97.2   (1.59)   97.2   (1.56)   97.0   (2.06)   0.453
   Temperature (°C)                           36.7             (0.57)      36.7   (0.59)   36.7   (0.55)   36.8   (0.49)   0.688

Numbers in bold denote statistical significance.

Symptom severity during follow-up {#s9}
---------------------------------

Compared to those without an organism, those with a viral infection alone (MD, 95% CI: 0.204, 0.010 to 0.398) and those with a combined viral and bacterial infection (MD, 95% CI: 0.348, 0.098 to 0.598) had higher symptom severity scores, while there was no difference in those with bacterial infection alone (MD, 95% CI: 0.192, -0.008 to 0.391) ([Table 3](#T3){ref-type="table"}). In the sensitivity analysis, we observed similar findings ([Supplementary Material 6](#sup6){ref-type="supplementary-material"}).

###### 

Symptom severity measured as the mean diary score for all symptoms during Days 2 to 4 after the baseline consultation in the prospective Cough Complication Cohort (3C) Plus study 2013

  Predictor                  *n*   Symptom severity   Unadjusted   Adjusted^a^                                      
  -------------------------- ----- ------------------ ------------ ------------- ---------------------- ----------- ----------------------
  Organism group                                                                                                    
   None                      161   1.23               (0.72)       \-            Reference              \-          Reference
   Viral                     78    1.43               (0.66)       **0.201**     **(0.008 to 0.393)**   **0.204**   **(0.010 to 0.398)**
   Bacterial                 68    1.40               (0.70)       0.170         (−0.032 to 0.371)      0.192       (−0.008 to 0.391)
   Both                      38    1.63               (0.79)       **0.392**     **(0.140 to 0.644)**   **0.348**   **(0.098 to 0.598)**
  *Haemophilus influenzae*                                                                                          
   No                        257   1.28               (0.70)       \-            Reference              \-          Reference
   Yes                       88    1.58               (0.73)       **0.295**     **(0.123 to 0.467)**   **0.272**   **(0.103 to 0.442)**
  *Picornavirus* ^b^                                                                                                
   No                        263   1.32               (0.71)       \-            Reference              \-          Reference
   Yes                       82    1.48               (0.74)       0.163         (−0.015 to 0.341)      0.116       (−0.062 to 0.293)

Numbers in bold denote statistical significance.

^a^Adjusted for age, antibiotic prescription and duration of illness. Analysis for specific organisms was also adjusted for viral co-infection for those with *Haemophilus influenzae*, and for bacterial co-infection for those with *Picornavirus*.

^b^Picornavirus group combines organisms identified as either in Enterovirus genus or *Rhinovirus* species.

For organisms with a prevalence \>10%, those with *H. influenzae* isolated (*n* = 88), compared to those without (*n* = 257), had higher severity scores (MD, 95% CI: 0.272, 0.103 to 0.442) but there was no difference in those with and without *Picornavirus* infections.

[Figure 1](#F1){ref-type="fig"} shows mean and 95% CI for the combined symptom severity score between Day 1 and Day 7 for all groups. Symptom severity appeared highest for those with both viral and bacterial infection combined, followed by those with a viral or bacterial infection alone. Severity of symptoms appeared lowest for those with no infection. In the sensitivity analysis, the differences in symptom severity between groups were similar, but the difference between the viral and the no infection group was more evident ([Supplementary Material 7](#sup7){ref-type="supplementary-material"}).

![Mean and 95% CI severity scores for all symptoms combined from Day 1 to Day 7 across groups in the prospective Cough Complication Cohort (3C) Plus study 2013.](cmz093f0001){#F1}

Severity scores of selected symptoms are shown in [Supplementary Material 8](#sup8){ref-type="supplementary-material"}. Those with a viral infection alone, and combined viral and bacterial infection, appeared to have higher severity scores for wheeze and blocked nose throughout the 7 days and this difference declined progressively. The severity scores for the groups were similar for the symptoms of dry cough, chills, muscle aches, and temperature. In the sensitivity analysis, similar patterns were observed, but the difference between the two groups with viral organisms and the group with no infection were more evident ([Supplementary Material 9](#sup9){ref-type="supplementary-material"}).

Duration of symptoms {#s10}
--------------------

After adjustment for age, antibiotic prescription, duration of illness, and co-infection, there were no differences detectable between groups ([Table 4](#T4){ref-type="table"}). In the sensitivity analysis, there were also no significant differences in duration of symptoms between organism groups ([Supplementary Material 10](#sup10){ref-type="supplementary-material"}). There were no differences in duration of symptoms rated as moderate or severe between those with and without *H. influenzae* or *Picornavirus* organisms.

###### 

Duration of symptoms rated by participants as moderate or severe after initial presentation (i.e. the last day on which a rating of moderate or severe was recorded in the diary for any symptom) in the prospective Cough Complication Cohort (3C) Plus study 2013

  Predictor                  *n*   Duration   Unadjusted   Adjusted^a^                             
  -------------------------- ----- ---------- ------------ ------------- ----------------- ------- -----------------
  Organism                                                                                         
   None                      162   4.40       (2.53)       \-            Reference         \-      Reference
   Viral                     78    4.65       (2.23)       0.25          (−0.39 to 0.89)   0.17    (−0.48 to 0.82)
   Bacterial                 69    4.55       (2.30)       0.15          (−0.52 to 0.82)   0.18    (−0.49 to 0.85)
   Both                      38    5.00       (2.03)       0.60          (−0.24 to 1.44)   0.51    (−0.33 to 1.35)
  *Haemophilus influenzae*                                                                         
   No                        259   4.42       (2.42)       \-            Reference         \-      Reference
   Yes                       88    4.94       (2.16)       0.52          (−0.05 to 1.09)   0.51    (−0.07 to 1.08)
  *Picornavirus* ^b^                                                                               
   No                        265   4.53       (2.44)       \-            Reference         \-      Reference
   Yes                       82    4.63       (2.14)       0.11          (−0.48 to 0.69)   −0.02   (−0.62 to 0.58)

^a^Adjusted for age, antibiotic prescription, and duration of illness. Analysis for specific organisms was also adjusted for viral co-infection for those with *Haemophilus influenzae*, and for bacterial co-infection for those with *Picornavirus*.

^b^Picornavirus group combines organisms identified as either in Enterovirus genus or *Rhinovirus* species.

In analyses including censoring participants whose rating of symptoms was missing on the following day, there were no differences (*P*-value for comparing four groups = 0.70) in the median (5--6 days) duration of symptoms rated by participants as moderate or severe ([Supplementary Material 11](#sup11){ref-type="supplementary-material"}), even after adjusting for confounders ([Supplementary Material 12](#sup12){ref-type="supplementary-material"}).

Discussion {#s11}
==========

Summary of principal findings {#s12}
-----------------------------

In primary care patients with acute cough, a potential pathogen could be detected in 53.6% of throat swabs and the prevalence of seven symptoms at presentation differed between organism groups. Symptom severity scores during follow-up were higher in those with a virus regardless of bacterial co-detection. However, there was no difference in the duration of symptoms rated as moderate or severe between organism groups. Adjusting for antibiotic prescription did not change these results. There were no differences in symptom severity or duration between those with and without the commonest virus and bacteria. By Day 7, most patients rated their symptoms as mild or less, including those symptoms rated as most severe initially.

Strengths and weaknesses of the study {#s13}
-------------------------------------

The recruitment of patients presenting with acute cough from routine consultations, using the same criteria as the 3C Study of more than 28,000 patients, was designed to make the study population widely generalizable. The diary response rate of only 54.8% was lower than for other studies of respiratory infection outcomes ([@CIT0014], [@CIT0016], [@CIT0028]). However, although those returning diaries were older and less likely to be current smokers, returning the symptoms diary was unrelated to the results of the microbiology of swabs ([Supplementary Material 4](#sup4){ref-type="supplementary-material"}). As diary data were available for a maximum of 7 days after initial presentation, around one-third of participants still had at least one moderate of severe symptom at the end of follow-up, and for these participants the time until all symptoms resolved was unknown.

The optimal site for sampling different organisms varies and increasing the number of sampling sites increases the detection rate ([@CIT0029]). We took a pragmatic decision to use oropharyngeal swabs, which are associated with disease prognosis and antimicrobial use ([@CIT0030]). Oropharyngeal swabs have also been used in studies on respiratory infections in children ([@CIT0024]), have the advantage of being available in nearly all patients, and improve uptake with busy clinicians and patients ([@CIT0024]). Therefore, they are of practical value as a future site for simple point of care testing.

The study had sufficient power for comparison to patients where no bacteria or viruses were found but limited power for comparisons between groups where bacteria or viruses were found. For the primary analysis of diary data, we used a similar classification of bacteria as pathogens as the GRACE study ([@CIT0004]) but including the full panel of bacteria in sensitivity analyses did not alter our conclusions. We had intended to investigate recovery for individual organisms with a prevalence \>10%, but due to our limited sample size, we could only investigate *Picornavirus* and *H. influenzae*. Thus, our grouping of individual organisms into broader groups may have obscured potentially important relationships that only much larger studies would be powered to detect. In past smokers, we observed significant differences in time since smoking cessation between organism groups, but as this variable was not associated with outcomes, we did not adjust for it in multivariable models.

Results in the context of other studies {#s14}
---------------------------------------

Clinicians place great weight on clinical signs in their decision to prescribe antibiotics ([@CIT0031]) and some signs, such as abnormal chest findings or discoloured sputum, are associated with antibiotic prescriptions ([@CIT0032]). However, clinical signs and clinician assessments are only modestly helpful for predicting pneumonia and the need for antibiotics ([@CIT0015], [@CIT0033], [@CIT0034]). Our study is consistent with these findings: differences that were detectable between groups for seven symptoms were small and unlikely to be helpful to clinicians in differentiating viral from bacterial infections.

In the placebo arms of RCTs of antibiotics in acute bronchitis, the mean number of days feeling ill ranges from 3 to 18 days ([@CIT0007]). and in a study of patients with more severe illness (most had chest signs and 13% pneumonia) who completed diaries, around 50% of patients describe themselves as being symptomatic 1 month after ALRTI ([@CIT0035]). In our study, the mean score for all symptoms declined over the 7 days and less than half described their symptoms as more than moderate. We used the mean symptom severity score on Days 2 to 4 after presentation since this is the period when symptoms are rated as worse by patients ([@CIT0023]) but, although there were differences between groups, these were small and unlikely to be meaningful to patients.

Nucleic acid amplification tests cannot distinguish between colonizing and causative organisms. In the GRACE study, viruses were found significantly more commonly in symptomatic illness and when these patients recovered ([@CIT0035]), the same viruses were found at a similar prevalence to those in controls again ([@CIT0004]). There have been similar findings in children ([@CIT0024]). Although we did not include controls or follow-up samples, seven symptoms were more common in patients with viral infections, regardless of whether they also had a bacterial infection, than in patients with a bacterial or no infection. Since neither the clinicians nor the patients were aware of the throat swab result at the time, it is unlikely bias accounted for these differences.

In our study, viruses alone were detected in 35.6% of patients, compared to 48.1% in GRACE. However, we did not include the peak period of influenza circulation ([@CIT0036]), which would explain most of this difference. In 299 participants (46.4%), we could not detect any respiratory viruses or pathogenic bacteria that we were investigating, which is similar to 41% of patients with ALRTI in the GRACE study in which no organism could be detected. Possible explanations include presentation of non-infective illnesses, such as cardiac conditions or malignancy ([@CIT0021]), or false-negative results: although the Taqman© assay is widely used and has high accuracy ([@CIT0037]), it is estimated that the organisms responsible for between 12 and 39% of lower respiratory infections are still to be identified ([@CIT0038]).

Implications {#s15}
------------

Antibiotics confer little benefit in non-pneumonic ALRTI ([@CIT0023]), but there is preliminary evidence from the GRACE study that patients with combined viral and bacterial infections could potentially benefit from antibiotics. This study provides further evidence that clinicians cannot easily differentiate on clinical grounds those who might be more likely to benefit and this is likely to contribute to the difficulty of reducing antibiotic prescribing. Larger data sets, including samples collected in different seasons, could establish whether grouping all viruses and bacteria together masks important relationships.

Conclusion {#s16}
==========

In primary care patients with ALRTI, differences in symptom prevalence at presentation and symptom severity score after consultation can be identified between patients with viruses and bacteria identified on throat swabs using real-time PCR. However, these differences are small, highlighting the difficulty facing clinicians, and unlikely to influence prescribing decisions for individual patients.
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